The main reason why cancer is so serious a disease, is the ability of the malignant cells to spread in the body, both locally by moving into nearby normal tissue, and regionally to nearby lymph nodes, tissues, or organs, affecting even … Continue reading
Tag Archives: Natco
Alarming Incidence of Cancer: Fragile Infrastructure: Escalating Drug Prices
According to the ‘Fact-Sheet 2014′ of the World Health Organization (WHO), cancer cases would rise from 14 million in 2012 to 22 million within the next two decades. It is, therefore, no wonder that cancers figured among the leading causes … Continue reading
India, China Revoke Four Pharma Patents in A Fortnight: A Double Whammy for MNCs?
Revocation of four pharma patents by India and China within a fortnight has raised many eyebrows, yet again, across the globe. In this short period, India has revoked three patents and China one. While this quick development is probably a … Continue reading
Does the Landmark Glivec Judgment Discourage Innovation in India?
No, I do not think so. The 112 pages well articulated judgment of the Supreme Court of India delivered on April 1, 2013, does not even remotely discourage innovation in India, including much talked about ‘incremental innovation’. This landmark judgment … Continue reading
An El Dorado…But Not Without Responsible Pricing:The Cancer Segment in India
The affordability issue for cancer treatment has been the subject of a raging debate since quite some time, as the incidence of cancer is fast increasing across the world. Just for example a very recent report highlighted that cancer has now become the … Continue reading
The Game Changers in 2012 and A Crystal Gazing into 2013
Wish You and Your Dear Ones Best of Health, Happiness, Success and Prosperity in The Brand New Year. Welcome 2013 The Global Pharmaceutical Industry (GPI), by and large, used to be considered as ‘recession-proof’ for various valid reasons. However, the … Continue reading
Grant of Compulsory License for Bayer’s Nexavar in India raises more questions than answers
On March 12, 2012, the Patent Office of India, in its landmark ruling, granted its first ever Compulsory License (CL) for Bayer’s patented kidney and liver cancer drug Nexavar (Sorafenib), to the generic pharma player Natco, broadly citing the following … Continue reading